{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-068614","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.390511+00:00","generated_at":"2026-05-16T00:16:46.031782+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Tempest reports 100% CR rate in REDEEM-1 trial; plans U.S. registrational study in 2026","bullets":["100% complete response (CR) rate among all six efficacy-evaluable patients in REDEEM-1 trial of TPST-2003 in rrMM.","Favorable safety profile: no Grade ≥3 CRS or ICANS across dose levels in REDEEM-1.","Prior 24-patient IIT showed 89.5% CR rate and median progression-free survival of 23.1 months.","Tempest plans to submit U.S. IND and initiate registrational study of TPST-2003 in 2026, subject to clearance.","Company exploring TPST-2003 in LBCL; expects initial data from TPST-3003 and TPST-4003 programs later in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-068614","json":"https://secwatch.observer/filing/0001193125-26-068614.json","markdown":"https://secwatch.observer/filing/0001193125-26-068614.md","text":"https://secwatch.observer/filing/0001193125-26-068614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526068614/0001193125-26-068614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526068614/d22967d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:16:46.031782+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}